the evaluation of these effects must take into consideration both the baseline renal and neurohormonal abnormalities in chf , and the cellular actions of pde iii inhibition , which include an increase in cyclic adenosine monophosphate and cytosolic calcium .
C0007634
cellular
C1383501
cytosolic